SeQuent Scientific Limited, a leading global player in animal healthcare, has announced the consolidation of its ownership in two key subsidiaries: N-VET AB, Sweden, and Alivira Italia SRL, Italy. Both entities are now wholly owned by the company following incremental stake acquisitions.
For N-VET AB, SeQuent acquired an additional 3.90% stake from Katarina Agren through its wholly owned subsidiary, Alivira Animal Health Limited, Ireland, for SEK 344,000. This acquisition raises SeQuent’s ownership from 96.10% to 100%, strengthening its presence in Sweden’s animal healthcare market.
In the case of Alivira Italia SRL, the company acquired a combined 5% stake from Renzo Rimondi (3.75%) and Ramon Vila Vina (1.25%) for €15,000. This increases SeQuent’s stake from 95% to full ownership, consolidating its foothold in the Italian market.
Both acquisitions, completed on November 22, 2024, are part of SeQuent’s strategy to enhance operational control and streamline decision-making across its global subsidiaries. N-VET AB and Alivira Italia SRL specialize in trading animal healthcare products, reinforcing SeQuent’s commitment to advancing its pharmaceuticals portfolio.
Phillip Trott, Company Secretary and Compliance Officer of SeQuent Scientific, stated that these transactions align with the company’s long-term objectives of growth and market consolidation.
